CTIS2023-504460-41-00进行中（未招募）1 期
AGMB-129-C103
Agomab Spain S.L.0 个研究点目标入组 24 人开始时间: 2023年6月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Assessment of narrowing of blood vessels after single application of two clascoterone formulations (cream and solution) onto the skin in comparison to three marketed topical corticosteroidsTest of vasocontriction properties for classification of topical steroid potencyMedDRA version: 20.0Level: LLTClassification code: 10047140Term: Vasoconstriction peripheral Class: 10047065CTIS2023-507241-28-00Cassiopea S.p.A.33
进行中（未招募）
1 期
Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgerySubjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resectionMedDRA version: 20.0Level: PTClassification code: 10018336Term: Glioblastoma Class: 100000004864CTIS2024-511171-15-00Celgene Corp.216
招募中
1 期
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).Acute myeloid leukemia or myelodysplastic syndrome of high risk group,that has come back after treatment or cannot be cured or treated by anyother known therapies.MedDRA version: 21.0Level: LLTClassification code: 10060558Term: Acute myeloid leukemia recurrent Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10081514Term: Acute myeloid leukemia refractory Class: 10029104CTIS2023-503869-34-00Celgene Corp.180
进行中（未招募）
1 期
A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects with Chronic Hepatitis B Virus Infectiochronic hepatitis B virus infection (cHBV)CTIS2024-511051-18-00Assembly Biosciences Inc.50
进行中（未招募）
1 期
MK-1403 Single Dose Formulation PK StudyMedDRA version: 20.0Level: LLTClassification code: 10003601Term: Atherosclerosis Class: 10047065AtherosclerosisCTIS2023-507984-20-00Merck Sharp & Dohme LLC16